| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| altiratinib | vascular endothelial growth factor receptor 2 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.17 | phase 1 | inhibitor |
| altiratinib | vascular endothelial growth factor receptor 2 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.17 | phase 1 | unknown |
| altiratinib | proto-oncogene c-met | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.51 | phase 1 | unknown |
| altiratinib | proto-oncogene c-met | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.51 | phase 1 | inhibitor |
| altiratinib | tropomyosin-related kinase a | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.28 | phase 1 | unknown |
| altiratinib | tropomyosin-related kinase a | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.28 | phase 1 | inhibitor |
| altiratinib | nt-3 growth factor receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.47 | phase 1 | inhibitor |
| altiratinib | nt-3 growth factor receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.47 | phase 1 | unknown |
| altiratinib | angiopoietin 1 receptor | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
1.33 | phase 1 | inhibitor |
| altiratinib | angiopoietin 1 receptor | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
1.33 | phase 1 | unknown |
| click here to return to the previous page | ||||||||